NEXTGEN HEALTHCARE INC (NXGN)
US65343C1027 - Common Stock
Taking everything into account, NXGN scores 4 out of 10 in our fundamental rating. NXGN was compared to 40 industry peers in the Health Care Technology industry. NXGN has only an average score on both its financial health and profitability. While showing a medium growth rate, NXGN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year NXGN was profitable.
NXGN had a negative operating cash flow in the past year.
NXGN had positive earnings in 4 of the past 5 years.
NXGN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -0.72%, NXGN is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
With a decent Return On Equity value of -1.47%, NXGN is doing good in the industry, outperforming 78.57% of the companies in the same industry.
NXGN has a better Return On Invested Capital (0.82%) than 78.57% of its industry peers.
NXGN had an Average Return On Invested Capital over the past 3 years of 1.91%. This is below the industry average of 4.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.72% | ||
| ROE | -1.47% | ||
| ROIC | 0.82% |
ROA(3y)0.48%
ROA(5y)1.41%
ROE(3y)0.64%
ROE(5y)2.06%
ROIC(3y)1.91%
ROIC(5y)2.95%
1.3 Margins
NXGN's Operating Margin of 1.06% is fine compared to the rest of the industry. NXGN outperforms 78.57% of its industry peers.
In the last couple of years the Operating Margin of NXGN has declined.
With a Gross Margin value of 46.40%, NXGN perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
In the last couple of years the Gross Margin of NXGN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.06% | ||
| PM (TTM) | N/A | ||
| GM | 46.4% |
OM growth 3Y-58.31%
OM growth 5Y-27.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y-2.66%
2. Health
2.1 Basic Checks
NXGN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for NXGN has been reduced compared to 1 year ago.
Compared to 5 years ago, NXGN has more shares outstanding
The debt/assets ratio for NXGN is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.59 indicates that NXGN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.59, NXGN is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
NXGN has a Debt/Equity ratio of 0.63. This is a neutral value indicating NXGN is somewhat dependend on debt financing.
NXGN has a Debt to Equity ratio of 0.63. This is in the lower half of the industry: NXGN underperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.59 |
ROIC/WACC0.08
WACC10.14%
2.3 Liquidity
NXGN has a Current Ratio of 2.52. This indicates that NXGN is financially healthy and has no problem in meeting its short term obligations.
NXGN has a Current ratio of 2.52. This is comparable to the rest of the industry: NXGN outperforms 50.00% of its industry peers.
A Quick Ratio of 2.52 indicates that NXGN has no problem at all paying its short term obligations.
NXGN has a Quick ratio (2.52) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.52 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 33.33% over the past year.
NXGN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.96% yearly.
Looking at the last year, NXGN shows a quite strong growth in Revenue. The Revenue has grown by 13.25% in the last year.
NXGN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.23% yearly.
EPS 1Y (TTM)33.33%
EPS 3Y5.69%
EPS 5Y6.96%
EPS growth Q2Q24%
Revenue 1Y (TTM)13.25%
Revenue growth 3Y6.53%
Revenue growth 5Y4.23%
Revenue growth Q2Q10.65%
3.2 Future
NXGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.15% yearly.
Based on estimates for the next years, NXGN will show a small growth in Revenue. The Revenue will grow by 7.76% on average per year.
EPS Next Y14.49%
EPS Next 2Y17.83%
EPS Next 3Y17.28%
EPS Next 5Y17.15%
Revenue Next Year11.2%
Revenue Next 2Y9.22%
Revenue Next 3Y8.41%
Revenue Next 5Y7.76%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.38 indicates a rather expensive valuation of NXGN.
NXGN's Price/Earnings ratio is rather cheap when compared to the industry. NXGN is cheaper than 92.86% of the companies in the same industry.
NXGN's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.20.
The Price/Forward Earnings ratio is 17.59, which indicates a rather expensive current valuation of NXGN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NXGN indicates a rather cheap valuation: NXGN is cheaper than 92.86% of the companies listed in the same industry.
NXGN's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.63.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.38 | ||
| Fwd PE | 17.59 |
4.2 Price Multiples
71.43% of the companies in the same industry are more expensive than NXGN, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 34.12 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as NXGN's earnings are expected to grow with 17.28% in the coming years.
PEG (NY)1.48
PEG (5Y)3.07
EPS Next 2Y17.83%
EPS Next 3Y17.28%
5. Dividend
5.1 Amount
No dividends for NXGN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEXTGEN HEALTHCARE INC
NASDAQ:NXGN (11/8/2023, 7:00:02 PM)
After market: 23.93 -0.01 (-0.04%)23.94
+0.03 (+0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.61B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.38 | ||
| Fwd PE | 17.59 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.48
PEG (5Y)3.07
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.72% | ||
| ROE | -1.47% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 1.06% | ||
| PM (TTM) | N/A | ||
| GM | 46.4% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.52 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)33.33%
EPS 3Y5.69%
EPS 5Y
EPS growth Q2Q
EPS Next Y14.49%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)13.25%
Revenue growth 3Y6.53%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y